Swedish Bluefish Pharmaceuticals AB wins exclusive tender in Germany
Bluefish Pharmaceuticals AB has secured the exclusive tender for two important products to GWQ ServicePlus AG in Germany. The contract is valid as of 1st of April 2010. GWQ is a cooperation of 36 health insurances in Germany, covering in total 4.2 million people. As such, GWQ is one of the largest groups in the German health insurance market. Bluefish will supply two products; Alendronate and Simvastatin. Alendronate belongs to the class of drugs called bisphosphonates and is commonly used in the treatment of osteoporosis. Simvastatin is a large volume product that is used for the treatment of high blood cholesterol. "Winning this contract is a major achievement and an important step in the continued establishment of Bluefish in Germany, the largest pharmaceutical market in the EU. Also, further strengthening of the Bluefish brand will have a positive effect on the overall product portfolio”, says Karl Karlsson, President and CEO of Bluefish Pharmaceuticals. This is the second exclusive tender that Bluefish has won in Germany. In November 2009, Bluefish was selected as the sole supplier of Mirtazapine ODT to the health insurance cooperation IKK gesund plus and IKK classic, which has a market share of 2.5%, equivalent to approximately 2 million people. The contract is valid for 2 years with initial product supply planned for January 2010. More information Karl Karlsson, President & CEO Bluefish Pharmaceuticals Tel. +46 8 679 50 70 Email: karl.karlsson@bluefishpharma.com Susanna Urdmark, CFO Bluefish Pharmaceuticals Tel. +46 8 679 50 70 Email: susanna.urdmark@bluefishpharma.com About Bluefish Pharmaceuticals Bluefish Pharmaceuticals offers high quality, cost effective generic pharmaceuticals of great medical value to patients. The company was founded in 2005 with the ambition to create a pan-European pharmaceutical company with focus on product development, registration and marketing. The company's product portfolio consists of 30 products, whereof 19 are approved in at least one European country, and another 11 are under registration. Bluefish has offices in Sweden, India, Austria, Germany, Italy and the Netherlands. www.bluefishpharma.com